Pharmacological management of nonalcoholic fatty liver disease

Metabolism: Clinical and Experimental

Volumn 65, Issue 8, 2016, Pages 1183-1195

  Barb, Diana ^a,b   Portillo Sanchez, Paola ^a,b   Cusi, Kenneth ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Dipeptidyl peptidase 4 (DPP 4) inhibitors; Glucagon like peptide 1 receptor agonists (GLP 1RA); Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Pioglitazone; Thiazolinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; BETAINE; BILE ACID; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LORCASERIN; METFORMIN; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PHOSPHODIESTERASE INHIBITOR; SELENIUM; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TETRAHYDROLIPSTATIN; ANTIDIABETIC AGENT;

ARTICLE; CLINICAL PRACTICE; DIETARY SUPPLEMENT; HUMAN; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); WEIGHT REDUCTION; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTOR;

ANTIOXIDANTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84979066985     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.04.004     Document Type: Article

References (152)

1. [1] Loomba, R, Sanyal, AJ, The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10:11 (2013), 686–690.
2. [2] Wong, RJ, Aguilar, M, Cheung, R, Perumpail, RB, Harrison, SA, Younossi, ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148:3 (2015), 547–555.
3. [3] Rinella, ME, Nonalcoholic fatty liver disease: a systematic review. JAMA 313 (2015), 2263–2273.
4. [4] Yang, L, Colditz, GA, Prevalence of overweight and obesity in the United States, 2007–2012. JAMA Intern Med 175:8 (2015), 1412–1413.
5. [5] Lomonaco, R, Chen, J, Cusi, K, An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Ther Adv Endocrinol Metab 2:5 (2011), 211–225.
6. [6] Brunt, EM, Kleiner, DE, Wilson, LA, Belt, P, Neuschwander-Tetri, BA, Network, NCR, Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53 (2011), 810–820.
7. [7] Hjelkrem, M, Stauch, C, Shaw, J, Harrison, SA, Validation of the non-alcoholic fatty liver disease activity score. Aliment Pharmacol Ther 34 (2011), 214–218.
8. [8] Angulo, P, Hui, JM, Marchesini, G, Bugianesi, E, George, J, Farrell, GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:4 (2007), 846–854.
9. [9] Browning, JD, Szczepaniak, LS, Dobbins, R, Nuremberg, P, Horton, JD, Cohen, JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:6 (2004), 1387–1395.
10. [10] Portillo-Sanchez, P, Bril, F, Maximos, M, Lomonaco, R, Biernacki, D, Orsak, B, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab 100 (2015), 2231–2238.
11. [11] Angulo, P, Kleiner, DE, Dam-Larsen, S, Adams, LA, Bjornsson, ES, Charatcharoenwitthaya, P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397 [e10].
12. [12] Ekstedt, M, Hagstrom, H, Nasr, P, Fredrikson, M, Stal, P, Kechagias, S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
13. [13] Singh, S, Allen, AM, Wang, Z, Prokop, LJ, Murad, MH, Loomba, R, Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13:4 (2015), 643–654 [e1-9; quiz e39-40].
14. [14] Pais, R, Charlotte, F, Fedchuk, L, Bedossa, P, Lebray, P, Poynard, T, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 59:3 (2013), 550–556.
15. [15] Argo, CK, Northup, PG, Al-Osaimi, AM, Caldwell, SH, Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 51:2 (2009), 371–379.
16. [16] Koehler, EM, Plompen, EP, Schouten, JN, Hansen, BE, Darwish Murad, S, Taimr, P, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology 63:1 (2016), 138–147.
17. [17] Lazo, M, Solga, SF, Horska, A, Bonekamp, S, Diehl, AM, Brancati, FL, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 33:10 (2010), 2156–2163.
18. [18] Larson-Meyer, DE, Heilbronn, LK, Redman, LM, Newcomer, BR, Frisard, MI, Anton, S, et al. Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 29:6 (2006), 1337–1344.
19. [19] Kantartzis, K, Thamer, C, Peter, A, Machann, J, Schick, F, Schraml, C, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 58:9 (2009), 1281–1288.
20. [20] Shah, K, Stufflebam, A, Hilton, TN, Sinacore, DR, Klein, S, Villareal, DT, Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring) 17:12 (2009), 2162–2168.
21. [21] Promrat, K, Kleiner, DE, Niemeier, HM, Jackvony, E, Kearns, M, Wands, JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51:1 (2010), 121–129.
22. [22] Harrison, SA, Fecht, W, Brunt, EM, Neuschwander-Tetri, BA, Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49:1 (2009), 80–86.
23. [23] Vilar-Gomez, E, Martinez-Perez, Y, Calzadilla-Bertot, L, Torres-Gonzalez, A, Gra-Oramas, B, Gonzalez-Fabian, L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149:2 (2015), 367–378 [e5; quiz e14-5].
24. [24] Lomonaco, R, Sunny, NE, Bril, F, Cusi, K, Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs 73:1 (2013), 1–14.
25. [25] Mahady, SE, George, J, Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism 65 (2015), 1172–1182.
26. [26] Mehal, WZ, Fain, R, Glicklich, A, Li, Y, Shanahan, W, Soliman, W, Lorcaserin Improves the NASH Clinical Score in the Majority of High-Risk Patients: a Retrospective Analysis of Three Phase 3 Studies. Hepatology, 61, 2014, 427A.
27. [27] Winokur, A, Halseth, A, Dybala, C, Lam, H, Chen, S, Chalasani, N, Naltrexone/Bupropion extended release 32 mg/360 mg significantly improves liver enzymes in obese/overweight individuals with elevated liver enzymes. Hepatology, 62, 2015, 1268A.
28. [28] Furuya, CK Jr., de Oliveira, CP, de Mello, ES, Faintuch, J, Raskovski, A, Matsuda, M, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol 22:4 (2007), 510–514.
29. [29] Lassailly, G, Caiazzo, R, Buob, D, Pigeyre, M, Verkindt, H, Labreuche, J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 149:2 (2015), 379–388 [quiz e15-6].
30. [30] Vargas, V, Allende, H, Lecube, A, Salcedo, MT, Baena-Fustegueras, JA, Fort, JM, et al. Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients. World J Hepatol 4:12 (2012), 382–388.
31. [31] Csendes, A, Smok, G, Burgos, AM, Histological findings in the liver before and after gastric bypass. Obes Surg 16:5 (2006), 607–611.
32. [32] Mathurin, P, Hollebecque, A, Arnalsteen, L, Buob, D, Leteurtre, E, Caiazzo, R, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137:2 (2009), 532–540.
33. [33] Watanabe, S, Hashimoto, E, Ikejima, K, Uto, H, Ono, M, Sumida, Y, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 50:4 (2015), 364–377.
34. [34] Sanyal, AJ, Chalasani, N, Kowdley, KV, McCullough, A, Diehl, AM, Bass, NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:18 (2010), 1675–1685.
35. [35] Lavine, JE, Schwimmer, JB, Van Natta, ML, Molleston, JP, Murray, KF, Rosenthal, P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305:16 (2011), 1659–1668.
36. [36] Miller, ER III, Pastor-Barriuso, R, Dalal, D, Riemersma, RA, Appel, LJ, Guallar, E, Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142 (2005), 37–46.
37. [37] Klein, EA, Thompson, IM Jr., Tangen, CM, Crowley, JJ, Lucia, MS, Goodman, PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306 (2011), 1549–1556.
38. [38] Machado, MV, Ravasco, P, Jesus, L, Marques-Vidal, P, Oliveira, CR, Proenca, T, et al. Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. Scand J Gastroenterol 43:1 (2008), 95–102.
39. [39] Pan, D, Huang, H, Hair selenium levels in hepatic steatosis patients. Biol Trace Elem Res 152:3 (2013), 305–309.
40. [40] Clarke, C, Baghdadi, H, Howie, AF, Mason, JI, Walker, SW, Beckett, GJ, Selenium supplementation attenuates procollagen-1 and interleukin-8 production in fat-loaded human C3A hepatoblastoma cells treated with TGFbeta1. Biochim Biophys Acta 1800:6 (2010), 611–618.
41. [41] Nido, SA, Shituleni, SA, Mengistu, BM, Liu, Y, Khan, AZ, Gan, F, et al. Effects of selenium-enriched probiotics on lipid metabolism, antioxidative status, histopathological lesions, and related gene expression in mice fed a high-fat diet. Biol Trace Elem Res, 2015.
42. [42] Kawakami, S, Han, KH, Nakamura, Y, Shimada, K, Kitano, T, Aritsuka, T, et al. Effects of dietary supplementation with betaine on a nonalcoholic steatohepatitis (NASH) mouse model. J Nutr Sci Vitaminol (Tokyo) 58:5 (2012), 371–375.
43. [43] Kathirvel, E, Morgan, K, Nandgiri, G, Sandoval, BC, Caudill, MA, Bottiglieri, T, et al. Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. Am J Physiol Gastrointest Liver Physiol 299:5 (2010), G1068–G1077.
44. [44] Abdelmalek, MF, Sanderson, SO, Angulo, P, Soldevila-Pico, C, Liu, C, Peter, J, et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 50 (2009), 1818–1826.
45. [45] Chalasani, N, Younossi, Z, Lavine, JE, Diehl, AM, Brunt, EM, Cusi, K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142:7 (2012), 1592–1609.
46. [46] Chalasani, N, Younossi, Z, Lavine, JE, Diehl, AM, Brunt, EM, Cusi, K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:6 (2012), 2005–2023.
47. [47] Lee, CC, Watkins, SM, Lorenzo, C, Wagenknecht, LE, Il'yasova, D, Chen, YI, et al. Branched-chain amino acids and insulin metabolism: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care, 2016.
48. [48] Magkos, F, Bradley, D, Schweitzer, GG, Finck, BN, Eagon, JC, Ilkayeva, O, et al. Effect of Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding on branched-chain amino acid metabolism. Diabetes 62:8 (2013), 2757–2761.
49. [49] Sunny, NE, Kalavalapalli, S, Bril, F, Garrett, TJ, Nautiyal, M, Mathew, JT, et al. Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab 309:4 (2015), E311–E319.
50. [50] Tanaka, H, Fukahori, S, Baba, S, Ueno, T, Sivakumar, R, Yagi, M, et al. Branched-chain amino acid-rich supplements containing microelements have antioxidant effects on nonalcoholic steatohepatitis in mice. JPEN J Parenter Enteral Nutr, 2014.
51. [51] Garcia Caraballo, SC, Comhair, TM, Houten, SM, Dejong, CH, Lamers, WH, Koehler, SE, High-protein diets prevent steatosis and induce hepatic accumulation of monomethyl branched-chain fatty acids. J Nutr Biochem 25:12 (2014), 1263–1274.
52. [52] Inzucchi, SE, Bergenstal, RM, Buse, JB, Diamant, M, Ferrannini, E, Nauck, M, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Diabetologia 58 (2015), 429–442.
53. [53] Loomba, R, Lutchman, G, Kleiner, DE, Ricks, M, Feld, JJ, Borg, BB, et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 29 (2009), 172–182.
54. [54] Bugianesi, E, Gentilcore, E, Manini, R, Natale, S, Vanni, E, Villanova, N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100 (2005), 1082–1090.
55. [55] Musso, G, Gambino, R, Cassader, M, Pagano, G, A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52 (2010), 79–104.
56. [56] Ratziu, V, Caldwell, S, Neuschwander-Tetri, BA, Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology 52 (2010), 2206–2215.
57. [57] Campbell, JE, Drucker, DJ, Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17 (2013), 819–837.
58. [58] Svegliati-Baroni, G, Saccomanno, S, Rychlicki, C, Agostinelli, L, De Minicis, S, Candelaresi, C, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 31 (2011), 1285–1297.
59. [59] Ding, X, Saxena, NK, Lin, S, Gupta, NA, Anania, FA, Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43 (2006), 173–181.
60. [60] Ben-Shlomo, S, Zvibel, I, Shnell, M, Shlomai, A, Chepurko, E, Halpern, Z, et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 54 (2011), 1214–1223.
61. [61] Lee, J, Hong, SW, Chae, SW, Kim, DH, Choi, JH, Bae, JC, et al. Exendin-4 improves steatohepatitis by increasing sirt1 expression in high-fat diet-induced obese C57BL/6 J mice. PLoS One, 7, 2012, e31394.
62. [62] Trevaskis, JL, Griffin, PS, Wittmer, C, Neuschwander-Tetri, BA, Brunt, EM, Dolman, CS, et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 302 (2012), G762–G772.
63. [63] Armstrong, MJ, Houlihan, DD, Rowe, IA, Clausen, WH, Elbrond, B, Gough, SC, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther 37:2 (2013), 234–242.
64. [64] Cuthbertson, DJ, Irwin, A, Gardner, CJ, Daousi, C, Purewal, T, Furlong, N, et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One, 7, 2012, e50117.
65. [65] Eguchi, Y, Kitajima, Y, Hyogo, H, Takahashi, H, Kojima, M, Ono, M, et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res 45 (2015), 269–278.
66. [66] Jendle, J, Nauck, MA, Matthews, DR, Frid, A, Hermansen, K, During, M, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 11 (2009), 1163–1172.
67. [67] Ohki, T, Isogawa, A, Iwamoto, M, Ohsugi, M, Yoshida, H, Toda, N, et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ScientificWorldJournal, 2012, 2012, 496453.
68. [68] Tang, A, Rabasa-Lhoret, R, Castel, H, Wartelle-Bladou, C, Gilbert, G, Massicotte-Tisluck, K, et al. Response to comment on Tang et al. Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial. Diabetes Care 2015;38:1339-1346. Diabetes Care 38:9 (2015), e150–e151.
69. [69] Armstrong, MJ, Gaunt, P, Aithal, GP, Barton, D, Hull, D, Parker, R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387:10019 (2016), 679–690.
70. [70] Armstrong, MJ, Hull, D, Guo, K, Barton, D, Hazlehurst, JM, Gathercole, LL, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatophepatitis. J Hepatol, 2015.
71. [71] Zarrinpar, A, Loomba, R, Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 36 (2012), 909–921.
72. [72] Shirakawa, J, Fujii, H, Ohnuma, K, Sato, K, Ito, Y, Kaji, M, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 60 (2011), 1246–1257.
73. [73] Iwasaki, T, Yoneda, M, Inamori, M, Shirakawa, J, Higurashi, T, Maeda, S, et al. Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology 58 (2011), 2103–2105.
74. [74] Fukuhara, T, Hyogo, H, Ochi, H, Fujino, H, Kan, H, Naeshiro, N, et al. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology 61 (2014), 323–328.
75. [75] Macauley, M, Hollingsworth, KG, Smith, FE, Thelwall, PE, Al-Mrabeh, A, Schweizer, A, et al. Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab 100 (2015), 1578–1585.
76. [76] Maximos, M, Bril, F, Portillo Sanchez, P, Lomonaco, R, Orsak, B, Biernacki, D, et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology 61 (2015), 153–160.
77. [77] Mudaliar, S, Polidori, D, Zambrowicz, B, Henry, RR, Sodium–glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care 38 (2015), 2344–2353.
78. [78] Zinman, B, Wanner, C, Lachin, JM, Fitchett, D, Bluhmki, E, Hantel, S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
79. [79] Hayashizaki-Someya, Y, Kurosaki, E, Takasu, T, Mitori, H, Yamazaki, S, Koide, K, et al. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol 754 (2015), 19–24.
80. [80] Yokono, M, Takasu, T, Hayashizaki, Y, Mitsuoka, K, Kihara, R, Muramatsu, Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 727 (2014), 66–74.
81. [81] Lavalle-Gonzalez, FJ, Januszewicz, A, Davidson, J, Tong, C, Qiu, R, Canovatchel, W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56 (2013), 2582–2592.
82. [82] Bailey, CJ, Gross, JL, Pieters, A, Bastien, A, List, JF, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375 (2010), 2223–2233.
83. [83] Soccio, RE, Chen, ER, Lazar, MA, Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 20 (2014), 573–591.
84. [84] Yau, H, Rivera, K, Lomonaco, R, Cusi, K, The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep 13 (2013), 329–341.
85. [85] Cusi, K, Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 142:4 (2012), 711–725 [e6].
86. [86] DeFronzo, RA, Tripathy, D, Schwenke, DC, Banerji, M, Bray, GA, Buchanan, TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364 (2011), 1104–1115.
87. [87] Belfort, R, Harrison, SA, Brown, K, Darland, C, Finch, J, Hardies, J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006), 2297–2307.
88. [88] Aithal, GP, Thomas, JA, Kaye, PV, Lawson, A, Ryder, SD, Spendlove, I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135 (2008), 1176–1184.
89. [89] Ratziu, V, Giral, P, Jacqueminet, S, Charlotte, F, Hartemann-Heurtier, A, Serfaty, L, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology 135 (2008), 100–110.
90. [90] Cusi, K, Orsak, B, Bril, F, Lomonaco, R, Hecht, J, Ortiz-Lopez, C, et al. Long-term piogltazone treatment for patients with NASH and prediabetes or T2DM: a randomized controlled trial. Ann Intern Med, 2016 [in press].
91. [91] Portillo, PY,S, Bril, F, Cusi, K, Role of insulin resistance and diabetes in the pathogenesis and treatment of nonalcoholic fatty Liver disease. Curr Hepatol Rep 13 (2014), 159–170.
92. [92] Lincoff, AM, Wolski, K, Nicholls, SJ, Nissen, SE, Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007), 1180–1188.
93. [93] Kernan, WN, Viscoli, CM, Furie, KL, Young, LH, Inzucchi, SE, Gorman, M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med, 2016.
94. [94] Schwartz, AV, Chen, H, Ambrosius, WT, Sood, A, Josse, RG, Bonds, DE, et al. Effects of TZD use and discontinuation on fracture rates in ACCORD bone study. J Clin Endocrinol Metab 100:11 (2015), 4059–4066.
95. [95] Zhu, ZN, Jiang, YF, Ding, T, Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 68 (2014), 115–123.
96. [96] Lewis, JD, Habel, LA, Quesenberry, CP, Strom, BL, Peng, T, Hedderson, MM, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 314 (2015), 265–277.
97. [97] Chang, CH, Lin, JW, Wu, LC, Lai, MS, Chuang, LM, Chan, KA, Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 55 (2012), 1462–1472.
98. [98] Monami, M, Dicembrini, I, Mannucci, E, Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials. Acta Diabetol 51 (2014), 91–101.
99. [99] Dasarathy, S, Dasarathy, J, Khiyami, A, Yerian, L, Hawkins, C, Sargent, R, et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 49 (2015), 137–144.
100. [100] Scorletti, E, Bhatia, L, McCormick, KG, Clough, GF, Nash, K, Hodson, L, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the WELCOME study. Hepatology 60 (2014), 1211–1221.
101. [101] Sanyal, AJ, Abdelmalek, MF, Suzuki, A, Cummings, OW, Chojkier, M, Group, E-AS, No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 147 (2014), 377–384.
102. [102] Parker, HM, Johnson, NA, Burdon, CA, Cohn, JS, O'Connor, HT, George, J, Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 56 (2012), 944–951.
103. [103] Bril, F., Lomonaco, R., Cusi, K., The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. Clinical Lipidology 7:4 (2012), 471–481.
104. [104] Eslami, L, Merat, S, Malekzadeh, R, Nasseri-Moghaddam, S, Aramin, H, Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev, 12, 2013, CD008623.
105. [105] Nelson, A, Torres, DM, Morgan, AE, Fincke, C, Harrison, SA, A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 43 (2009), 990–994.
106. [106] Enjoji, M, Machida, K, Kohjima, M, Kato, M, Kotoh, K, Matsunaga, K, et al. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis, 9, 2010, 29.
107. [107] Chan, DC, Watts, GF, Gan, SK, Ooi, EM, Barrett, PH, Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 33 (2010), 1134–1139.
108. [108] Yoneda, M, Fujita, K, Nozaki, Y, Endo, H, Takahashi, H, Hosono, K, et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol Res 40:6 (2010), 566–573.
109. [109] Fabbrini, E, Mohammed, BS, Korenblat, KM, Magkos, F, McCrea, J, Patterson, BW, et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 95:6 (2010), 2727–2735.
110. [110] Le, TA, Chen, J, Changchien, C, Peterson, MR, Kono, Y, Patton, H, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 56:3 (2012), 922–932.
111. [111] Pawlak, M, Lefebvre, P, Staels, B, Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol 62:3 (2015), 720–733.
112. [112] Belfort, R, Berria, R, Cornell, J, Cusi, K, Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 95:2 (2010), 829–836.
113. [113] Bril, F, Sninsky, JJ, Baca, AM, Superko, HR, Portillo Sanchez, P, Biernacki, D, et al. Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD. J Clin Endocrinol Metab 101:2 (2016), 644–652.
114. [114] Ginsberg, HN, Elam, MB, Lovato, LC, Crouse, JR 3rd, Leiter, LA, Linz, P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362:17 (2010), 1563–1574.
115. [115] Fernandez-Miranda, C, Perez-Carreras, M, Colina, F, Lopez-Alonso, G, Vargas, C, Solis-Herruzo, JA, A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 40:3 (2008), 200–205.
116. [116] Fruchart, JC, Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alpha-agonists. Cardiovasc Diabetol, 12, 2013, 82.
117. [117] Arai, H, Ishibashi, S, Yamashita, S, Araki, E, Yokote, K, Suganami, H, et al. Efficacy and safety of K-877, a potent and selective PPAR-α modulator (SPPARMα), in combination with statins in Japanese patients with dyslipidemia. Circulation, 2015 [Abstract 13374].
118. [118] Henry, RR, Lincoff, AM, Mudaliar, S, Rabbia, M, Chognot, C, Herz, M, Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 374:9684 (2009), 126–135.
119. [119] Lincoff, AM, Tardif, JC, Schwartz, GG, Nicholls, SJ, Ryden, L, Neal, B, et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 311:15 (2014), 1515–1525.
120. [120] Cariou, B, Zair, Y, Staels, B, Bruckert, E, Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 34:9 (2011), 2008–2014.
121. [121] Ratziu, V, Harrison, S, Francque, S, Bedossa, P, Lehert, P, Serfaty, L, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology, 2016.
122. [122] Staels, B, Rubenstrunk, A, Noel, B, Rigou, G, Delataille, P, Millatt, LJ, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 58:6 (2013), 1941–1952.
123. [123] Cariou, B, Hanf, R, Lambert-Porcheron, S, Zair, Y, Sauvinet, V, Noel, B, et al. Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 36:10 (2013), 2923–2930.
124. [124] Li, W, Zheng, L, Sheng, C, Cheng, X, Qing, L, Qu, S, Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis, 10, 2011, 49.
125. [125] Van Wagner, LB, Koppe, SW, Brunt, EM, Gottstein, J, Gardikiotes, K, Green, RM, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 10 (2011), 277–286.
126. [126] Zein, CO, Yerian, LM, Gogate, P, Lopez, R, Kirwan, JP, Feldstein, AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 54 (2011), 1610–1619.
127. [127] Ratziu, V, Bedossa, P, Francque, SM, Larrey, D, Aithal, GP, Serfaty, L, et al. Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 12:10 (2014), 1724–1730 [e5].
128. [128] Lindor, KD, Kowdley, KV, Heathcote, EJ, Harrison, ME, Jorgensen, R, Angulo, P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39:3 (2004), 770–778.
129. [129] Safadi, R, Konikoff, FM, Mahamid, M, Zelber-Sagi, S, Halpern, M, Gilat, T, et al. The fatty acid–bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 12:12 (2014), 2085–2091 [e1].
130. [130] Ijssennagger, N, Janssen, AW, Milona, A, Ramos Pittol, JM, Hollman, DA, Mokry, M, et al. Gene expression profiling in human precision cut liver slices upon treatment with the FXR agonist obeticholic acid. J Hepatol, 2016.
131. [131] Cipriani, S, Mencarelli, A, Palladino, G, Fiorucci, S, FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 51:4 (2010), 771–784.
132. [132] Fickert, P, Fuchsbichler, A, Moustafa, T, Wagner, M, Zollner, G, Halilbasic, E, et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 175:6 (2009), 2392–2405.
133. [133] Verbeke, L, Farre, R, Trebicka, J, Komuta, M, Roskams, T, Klein, S, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59:6 (2014), 2286–2298.
134. [134] Neuschwander-Tetri, BA, Loomba, R, Sanyal, AJ, Lavine, JE, Van Natta, ML, Abdelmalek, MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
135. [135] Zelber-Sagi, S, Kessler, A, Brazowsky, E, Webb, M, Lurie, Y, Santo, M, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 4:5 (2006), 639–644.
136. [136] Hatzitolios, A, Savopoulos, C, Lazaraki, G, Sidiropoulos, I, Haritanti, P, Lefkopoulos, A, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 23:4 (2004), 131–134.
137. [137] Hussein, O, Grosovski, M, Schlesinger, S, Szvalb, S, Assy, N, Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). Dig Dis Sci 52:10 (2007), 2512–2519.
138. [138] Fidler, MC, Sanchez, M, Raether, B, Weissman, NJ, Smith, SR, Shanahan, WR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 96:10 (2011), 3067–3077.
139. [139] Apovian, CM, Aronne, LJ, Bessesen, DH, McDonnell, ME, Murad, MH, Pagotto, U, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100:2 (2015), 342–362.
140. [140] Greenway, FL, Fujioka, K, Plodkowski, RA, Mudaliar, S, Guttadauria, M, Erickson, J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376:9741 (2010), 595–605.
141. [141] Allison, DB, Gadde, KM, Garvey, WT, Peterson, CA, Schwiers, ML, Najarian, T, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 20:2 (2012), 330–342.
142. [142] Pi-Sunyer, X, Astrup, A, Fujioka, K, Greenway, F, Halpern, A, Krempf, M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373:1 (2015), 11–22.
143. [143] Yokohama, S, Tokusashi, Y, Nakamura, K, Tamaki, Y, Okamoto, S, Okada, M, et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 12:2 (2006), 322–326.
144. [144] Paschos, P, Tziomalos, K, Nonalcoholic fatty liver disease and the renin-angiotensin system: implications for treatment. World J Hepatol 4:12 (2012), 327–331.
145. [145] Yokohama, S, Yoneda, M, Haneda, M, Okamoto, S, Okada, M, Aso, K, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40:5 (2004), 1222–1225.
146. [146] Georgescu, EF, Ionescu, R, Niculescu, M, Mogoanta, L, Vancica, L, Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 15:8 (2009), 942–954.
147. [147] Torres, DM, Jones, FJ, Shaw, JC, Williams, CD, Ward, JA, Harrison, SA, Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology 54:5 (2011), 1631–1639.
148. [148] Ortiz-Lopez, C, Lomonaco, R, Orsak, B, Finch, J, Chang, Z, Kochunov, VG, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 35:4 (2012), 873–878.
149. [149] Kwok, R, Choi, KC, Wong, GL, Zhang, Y, Chan, HL, Luk, AO, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut, 2015.
150. [150] Rinella, ME, Lominadze, Z, Loomba, R, Charlton, M, Neuschwander-Tetri, BA, Caldwell, SH, et al. Practice patterns in NAFLD and NASH: real life differs from published guidelines. Therap Adv Gastroenterol 9:1 (2016), 4–12.
151. [151] Filozof, C, Goldstein, BJ, Williams, RN, Sanyal, A, Non-Alcoholic Steatohepatitis: Limited available treatment options but promising drugs in development and recent progress towards a regulatory approval pathway. Drugs 75 (2015), 1373–1392.
152. [152] Harrison, SA, NASH, from diagnosis to treatment: Where do we stand?. Hepatology 62 (2015), 1652–1655.